HPA007308

antibody from Atlas Antibodies

Targeting: NQO1 DHQU, DIA4, DTD, NMOR1, QR1

Provider product page for HPA007308

Western blot

Immunocytochemistry

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [22]
Comments [0]
Validations
Immunohistochemistry [1]

Submit

Product number: HPA007308 - Provider product page
Provider: Atlas Antibodies
Proper citation: Atlas Antibodies Cat#HPA007308, RRID:AB_1079501
Product name: Anti-NQO1
Antibody type: Polyclonal
Description: Polyclonal Antibody against Human NQO1, Gene description: NAD(P)H dehydrogenase, quinone 1, Alternative Gene Names: DHQU, DIA4, DTD, NMOR1, QR1, Validated applications: WB, IHC, ICC, Uniprot ID: P15559, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Reactivity: Human
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 100 µl
Concentration: 0.2 mg/ml
Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
Handling: The antibody solution should be gently mixed before use.

NQO1 protein structure - HPA007308 shown in red.

Submitted references Glutathione synthesis in the mouse liver supports lipid abundance through NRF2 repression

Asantewaa G, Tuttle E, Ward N, Kang Y, Kim Y, Kavanagh M, Girnius N, Chen Y, Rodriguez K, Hecht F, Zocchi M, Smorodintsev-Schiller L, Scales T, Taylor K, Alimohammadi F, Duncan R, Sechrist Z, Agostini-Vulaj D, Schafer X, Chang H, Smith Z, O’Connor T, Whelan S, Selfors L, Crowdis J, Gray G, Bronson R, Brenner D, Rufini A, Dirksen R, Hezel A, Huber A, Munger J, Cravatt B, Vasiliou V, Cole C, DeNicola G, Harris I
Nature Communications 2024;15(1)

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

Zavitsanou A, Pillai R, Hao Y, Wu W, Bartnicki E, Karakousi T, Rajalingam S, Herrera A, Karatza A, Rashidfarrokhi A, Solis S, Ciampricotti M, Yeaton A, Ivanova E, Wohlhieter C, Buus T, Hayashi M, Karadal-Ferrena B, Pass H, Poirier J, Rudin C, Wong K, Moreira A, Khanna K, Tsirigos A, Papagiannakopoulos T, Koralov S
Cell Reports 2023;42(11):113295

Transcription Factor NFE2L1 Decreases in Glomerulonephropathies after Podocyte Damage.

Elshani M, Um IH, Leung S, Reynolds PA, Chapman A, Kudsy M, Harrison DJ
Cells 2023 Aug 29;12(17)

Asantewaa G, Tuttle E, Ward N, Kang Y, Kim Y, Kavanagh M, Girnius N, Chen Y, Duncan R, Rodriguez K, Hecht F, Zocchi M, Smorodintsev-Schiller L, Scales T, Taylor K, Alimohammadi F, Sechrist Z, Agostini-Vulaj D, Schafer X, Chang H, Smith Z, O’Connor T, Whelan S, Selfors L, Crowdis J, Gray G, Bronson R, Brenner D, Rufini A, Dirksen R, Hezel A, Huber A, Munger J, Cravatt B, Vasiliou V, Cole C, DeNicola G, Harris I
2023

A CRISPR screen identifies redox vulnerabilities for KEAP1/NRF2 mutant non-small cell lung cancer

Jiang C, Ward N, Prieto-Farigua N, Kang Y, Thalakola A, Teng M, DeNicola G
Redox Biology 2022;54

Spatial Analysis of NQO1 in Non-Small Cell Lung Cancer Shows Its Expression Is Independent of NRF1 and NRF2 in the Tumor Microenvironment

Kaghazchi B, Um I, Elshani M, Read O, Harrison D
Biomolecules 2022;12(11):1652

Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition

Ding H, Chen Z, Wu K, Huang S, Wu W, LeBoeuf S, Pillai R, Rabinowitz J, Papagiannakopoulos T
Science Advances 2021;7(47)

ATDC binds to KEAP1 to drive NRF2-mediated tumorigenesis and chemoresistance in pancreatic cancer

Purohit V, Wang L, Yang H, Li J, Ney G, Gumkowski E, Vaidya A, Wang A, Bhardwaj A, Zhao E, Dolgalev I, Zamperone A, Abel E, Magliano M, Crawford H, Diolaiti D, Papagiannakopoulos T, Lyssiotis C, Simeone D
Genes & Development 2021;35(3-4):218-233

Activation of Oxidative Stress Response in Cancer Generates a Druggable Dependency on Exogenous Non-essential Amino Acids

LeBoeuf S, Wu W, Karakousi T, Karadal B, Jackson S, Davidson S, Wong K, Koralov S, Sayin V, Papagiannakopoulos T
Cell Metabolism 2020;31(2):339-350.e4

Inhibition of TXNRD or SOD1 overcomes NRF2-mediated resistance to β-lapachone

Torrente L, Prieto-Farigua N, Falzone A, Elkins C, Boothman D, Haura E, DeNicola G
Redox Biology 2020;30

Nicotinamide nucleotide transhydrogenase regulates mitochondrial metabolism in NSCLC through maintenance of Fe-S protein function

Ward N, Kang Y, Falzone A, Boyle T, DeNicola G
Journal of Experimental Medicine 2020;217(6)

Retracted: NQO1 promotes an aggressive phenotype in hepatocellular carcinoma via amplifying ERK‐NRF2 signaling

Yang Y, Zheng J, Wang M, Zhang J, Tian T, Wang Z, Yuan S, Liu L, Zhu P, Gu F, Fu S, Shan Y, Pan Z, Zhou W
Cancer Science 2020;112(2):641-654

Zone-specific damage of the olfactory epithelium under protein restriction

Tuerdi A, Kikuta S, Kinoshita M, Kamogashira T, Kondo K, Yamasoba T
Scientific Reports 2020;10(1)

Keap1 mutation renders lung adenocarcinomas dependent on Slc33a1

Romero R, Sánchez-Rivera F, Westcott P, Mercer K, Bhutkar A, Muir A, González Robles T, Lamboy Rodríguez S, Liao L, Ng S, Li L, Colón C, Naranjo S, Beytagh M, Lewis C, Hsu P, Bronson R, Vander Heiden M, Jacks T
Nature Cancer 2020;1(6):589-602

Cysteine dioxygenase 1 is a metabolic liability for non-small cell lung cancer

Kang Y, Torrente L, Falzone A, Elkins C, Liu M, Asara J, Dibble C, DeNicola G
eLife 2019;8

Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer

Fiorillo M, Sotgia F, Sisci D, Cappello A, Lisanti M
Oncotarget 2017;8(12):20309-20327

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis

Romero R, Sayin V, Davidson S, Bauer M, Singh S, LeBoeuf S, Karakousi T, Ellis D, Bhutkar A, Sánchez-Rivera F, Subbaraj L, Martinez B, Bronson R, Prigge J, Schmidt E, Thomas C, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier J, Moreira A, Rudin C, Pass H, Vander Heiden M, Jacks T, Papagiannakopoulos T
Nature Medicine 2017;23(11):1362-1368

Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma

Dayton T, Gocheva V, Miller K, Israelsen W, Bhutkar A, Clish C, Davidson S, Luengo A, Bronson R, Jacks T, Vander Heiden M
Genes & Development 2016;30(9):1020-1033

Integrated transcriptomic and proteomic analyses uncover regulatory roles of Nrf2 in the kidney

Shelton L, Lister A, Walsh J, Jenkins R, Wong M, Rowe C, Ricci E, Ressel L, Fang Y, Demougin P, Vukojevic V, O'Neill P, Goldring C, Kitteringham N, Park B, Odermatt A, Copple I
Kidney International 2015;88(6):1261-1273

Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets

Schulze K, Imbeaud S, Letouzé E, Alexandrov L, Calderaro J, Rebouissou S, Couchy G, Meiller C, Shinde J, Soysouvanh F, Calatayud A, Pinyol R, Pelletier L, Balabaud C, Laurent A, Blanc J, Mazzaferro V, Calvo F, Villanueva A, Nault J, Bioulac-Sage P, Stratton M, Llovet J, Zucman-Rossi J
Nature Genetics 2015;47(5):505-511

NRF2 regulates serine biosynthesis in non–small cell lung cancer

DeNicola G, Chen P, Mullarky E, Sudderth J, Hu Z, Wu D, Tang H, Xie Y, Asara J, Huffman K, Wistuba I, Minna J, DeBerardinis R, Cantley L
Nature Genetics 2015;47(12):1475-1481

Idebenone Protects against Retinal Damage and Loss of Vision in a Mouse Model of Leber’s Hereditary Optic Neuropathy

Paul F, Heitz F, Erb M, Anklin C, Robay D, Pernet V, Gueven N
PLoS ONE 2012;7(9):e45182

No comments: Submit comment

Supportive validation

Submitted by: Atlas Antibodies (provider)
Enhanced method: Orthogonal validation
Main image
Experimental details: Immunohistochemistry analysis in human stomach and lymph node tissues using HPA007308 antibody. Corresponding NQO1 RNA-seq data are presented for the same tissues.
Sample type: Human
Protocol: Protocol
Orthogonal method: Orthogonal validation of protein expression using IHC by comparison to RNA-seq data of corresponding target in high and low expression tissues.

: Show more